Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...
Palvella Therapeutics Inc (PVLA) advances its Qtorin rapamycin NDA toward a February 2027 PDUFA date while funding a standalone U.S. launch and a deep pipeline of first-in-disease programs. Related Stocks: PVLA ,